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Abstract
Background: Despite the worldwide increasing burden of diabetes, there has been no corresponding scale-up
of treatment in developing countries and limited evidence of program effectiveness. In 2002, in collaboration with
the Ministry of Health of Cambodia, Médecins Sans Frontières initiated an outpatient program of subsidized
diabetic care in two hospital-based chronic disease clinics in rural settings. We aimed to describe the outcomes
of newly and previously diagnosed diabetic patients enrolled from 2002 to 2008.
Methods: We calculated the mean and proportion of patients who met the recommended treatment targets,
and the drop from baseline values for random blood glucose (RBG), hemoglobin A1c (HbA1c), blood pressure
(BP), and body mass index (BMI) at regular intervals. Analysis was restricted to patients not lost to follow-up. We
used the t test to compare baseline and subsequent paired values.
Results: Of 4404 patients enrolled, 2,872 (65%) were still in care at the time of the study, 24 (0.5%) had died,
and 1,508 (34%) were lost tofollow-up. Median age was 53 years, 2,905 (66%) were female and 4,350 (99%) had
type 2 diabetes. Median (interquartile range (IQR)) follow-up was 20 months (5 to 39.5 months). A total of 24%
(51/210) of patients had a HbA1c concentration of <7% and 35% (709/1,995) had a RBG <145 mg/dl within 1 year.
There was a significant drop of 109 mg/dl (95% confidence interval (CI) 103.1 to 114.3) in mean RBG (P < 0.001)
and a drop of 2.7% (95% CI 2.3 to 3.0) in mean HbA1c (P < 0.001) between baseline and month 6. In all, 45% (327/
723) and 62% (373/605) of patients with systolic or diastolic hypertension at baseline, respectively, reached = 130/
80 mm Hg within 1 year. There was a drop of 13.5 mm Hg (95% CI 12.1 to 14.9) in mean systolic blood pressure
(SBP) (P < 0.001), and a drop of 11.7 mm Hg (95% CI 10.8 to 12.6) in mean diastolic blood pressure (DBP) (P <
0.001) between baseline and month 6. Only 22% (90/401) patients with obesity at baseline lowered their BMI
<27.5 kg/m2 after 1 year. Factors associated with loss to follow-up were male sex, age >60 years, living outside
the province, normal BMI on admission, high RBG on last visit, and coming late for the last consultation.
Conclusion: Significant and clinically important improvements in glycemia and BP were observed, but a relatively
low proportion of diabetic patients reached treatment targets. These results and the high loss to follow-up rate
highlight the challenges of delivering diabetic care in rural, resource-limited settings.
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Background
Despite the increasing burden of chronic diseases in the
world and the fact that they have now become diseases of
poor people in most settings, the needs of these patients
have remained largely unmet [1]. Recently, the burden of
chronic conditions was assessed in 23 low and middle
income countries, showing that they accounted for 50%
of the total disease burden in 2005 and were associated
with higher estimated death rates in low and middle
income countries than in high income countries [2].
The total number of patients with diabetes, one of the
most common chronic diseases, is expected to climb from
110 million in 2000 to 317 million by 2030 according to
the World Health Organization (WHO) estimates [3]. In
Cambodia, recent surveys revealed a diabetes prevalence
of 11% in a semi-urban community and an unexpectedly
high prevalence of 5% in a relatively poor, traditional,
rural community [4]. An estimated 255 000 people live
with diabetes today in Cambodia.
Untreated diabetes is associated with uncontrolled hyper-
glycemia that gives rise to the risk of microvascular dam-
age (retinopathy, nephropathy and neuropathy) and
macrovascular complications (ischemic heart disease,
stroke and peripheral vascular disease), diminished qual-
ity of life and reduced life expectancy. There is now ample
evidence that good glycemic control reduces the risk of
vascular complications [5-7].
Despite this, access to diabetic care is still limited in devel-
oping countries, including Cambodia, and evaluation of
care is even more limited. Outcomes of diabetic care man-
agement, which generally include measurement of glyc-
emic control and other risk factors such as blood pressure
(BP) of large patient cohorts and treatment adherence, is
well described in industrialized countries [8-11] whereas
there are very few studies of the quality of diabetic care in
resource-limited contexts.
In 2002 Médecins Sans Frontières (MSF), in collaboration
with the Ministry of Health of Cambodia, initiated a pro-
gram to provide care for diabetes and hypertension in two
public hospital clinics in rural locations. The similarities
between the management of these two chronic conditions
and HIV/AIDS led MSF to set up a Chronic Disease Clinic
offering integrated care for both HIV/AIDS patients and
those suffering from diabetes and/or hypertension. This
novel experience that demonstrated the feasibility of inte-
grating care for chronic diseases with HIV/AIDS has been
published [12]. However, the outcomes of the diabetic
patient management have not been fully reported. The
purpose of this study is to describe the outcomes of a 5-
year diabetic treatment program in a high-prevalence but
low-resourcecountry.
Methods
Program description
We initiated the diabetic treatment program in March
2002 in Siem Reap province (population 700,000) and in
March 2003 in Takeo province (population 800,000). The
programs consisted of outpatient clinics at the public
referral hospital level and operated similarly in both loca-
tions. We provided integrated, patient-centered care (sim-
ilar to that offered to HIV-positive patients) for those with
diabetes, as has been described previously. [12] For diabe-
tes, we enrolled patients with types 1 or 2 and, while we
included only patients >15 years old at Siem Reap,
patients of all ages were seen at Takeo. Many patients had
been previously diagnosed with diabetes, either by a local
health provider or a laboratory. Between a quarter and a
third of individuals were taking oral antidiabetic drugs at
time of first consultation. The clinic staff included general
practitioners and nurses trained in diabetes care, drug
educators, adherence counselors, a receptionist and sup-
port staff to facilitate patient flow. Those same health per-
sonnel also attended patients with other chronic
conditions (HIV/AIDS, hypertension). MSF subsidized
care: patients were required to pay the initial registration
fee (US$1.00), a fee for diabetic and antihypertensive
drugs (US$1.10 for a 3-month treatment of glibenclamide
and US$4.50 for a 3-month treatment of metformin) until
mid-2005, and transportation costs. However, from mid-
2005 onward, all drugs were free of charge. Transporta-
tion costs for patients were never covered by the program.
Standardized care and follow-up procedures
We defined criteria for the diagnosis of diabetes type 2 as:
fasting blood glucose greater than 126 mg/dl on at least
two occasions, or random blood glucose (RBG) greater
than 200 mg/dl on one occasion with accompanying
symptoms and signs of diabetes. We defined diabetes type
1 as child-onset diabetes. Patient admissions were some-
what restricted in 2007 due to high workload.
Advice on exercise and appropriate diet was given to
patients on an individual basis. Until 2005 this was pro-
vided at the end of the consultation by the doctor, and
after 2005 by a nurse in a separate counseling session.
However, due to human resources constraints (until 2007
only one nurse was involved in health education), most
patients attended only one to two 40-min sessions.
We employed an oral hypoglycemic agent as mono-
therapy when medical treatment was required: metformin
if body mass index (BMI) ≥23 kg/m2, and glibenclamide
if BMI <23 kg/m2 and/or if there were contraindications to
metformin. A second oral agent was added for patients
failing to reach glucose control with monotherapy. We
reserved insulin therapy for patients with child-onset dia-
betes, pregnancy, or those with moderate to severe renalBMC Medicine 2009, 7:33 http://www.biomedcentral.com/1741-7015/7/33
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impairment. Other non-diabetic drugs such as antihyper-
tensive drugs were used if required clinically. Antihyper-
tensive drugs were started immediately in patients with BP
>130/80 and target organ damage. Otherwise, pharmaco-
therapy was initiated if BP was not controlled (<130/80)
3 months after advice on lifestyle modifications was given
to the patient. Angiotensin-converting enzyme (ACE)
inhibitors were prescribed as first line antihypertensive
therapy. A β blocker was used in patients with cardiac dis-
ease. Drugs from other classes, diuretics and calcium
inhibitors were added if combination therapy was
needed.
We saw patients after treatment initiation every 1 to 2
weeks, then monthly and eventually every 3 months once
glycemia was controlled (RBG <200 mg/dl). At each fol-
low-up visit, we measured blood glucose level, weight and
BP, and performed clinical screening for complications.
BP was measured seated after 5 min rest and involved at
least two readings on the same day. We checked for treat-
ment acceptance, tolerance, and adherence with open-
ended questions. If drug intake was irregular, counselors
provided adherence advice and support. A patient was
defined as lost to follow-up (LTFU) if their last contact
with the clinic was more than 3 months before and they
were not known to be dead or to have transferred out of
the area.
We measured glucose levels in capillary blood using a glu-
cometer (OneTouch Basic 200-200; LifeScan, Milpitas,
California, USA). In case of very high blood glucose levels,
>600 mg/dl, we took venous blood for glucose measure-
ment at the hospital laboratory. Until 2007, due to lack of
resources, clinicians generally performed RBG tests in the
morning to estimate overall glycemic control and used the
cut-off value of 180 mg/dl (10 mmol/l) as an acceptable
level [13]. For most patients, baseline RBG was measured
between 1.5 to 2 h after breakfast taken at home (typically
a light meal high in carbohydrates, since they often had to
walk a considerable distance for their appointment). Sys-
tematic measurement of hemoglobin A1c (HbA1c) (D-10;
high-performance liquid chromatography (HPLC)
method) at baseline and on a quarterly basis for monitor-
ing glucose control at the individual level started in 2007.
Hence, clinicians used RBG to monitor response to treat-
ment for the majority of the patients for most of their fol-
low-up period.
Data collection
We recorded clinical information on standardized clinical
files specifically designed for diabetic care. Information
on all patients was collected prospectively and entered
into an electronic medical record software program devel-
oped locally, specifically for chronic diseases. Trained per-
sonnel extracted clinical, treatment, and laboratory data
from individual patient records daily and entered them
into the database. A full time data manager routinely
checked data entry for accuracy and completeness.
Statistical analysis
Descriptive statistics (frequency, median, 25th and 75th
quartiles, proportion) were used to describe characteris-
tics at admission and status at the end of study period of
all patients, both newly and previously diagnosed with
diabetes in the program and who came for at least one
consultation between March 2002 until mid-2008 in
Takeo and Siem Reap clinics.
The analysis of blood sugar, BP and BMI evolution over
treatment time was limited to patients not LTFU and with
at least baseline and end of follow-up values. We deter-
mined the proportion of the patients who met the recom-
mended targets for RBG, HbA1c, BP and BMI at regular
intervals after enrolment in the program. For this target
analysis, only patients with elevated baseline BMI (≥23.0)
were included, for systolic blood pressure (SBP) only
patients with elevated baseline SBP (>130 mm Hg) were
included, and for diastolic blood pressure (DBP) only
patients with elevated baseline DBP (>80 mm Hg) were
included. We used the recommended glycemia (RBG
<145 mg/dl) and BP targets (130/80) for type 2 diabetic
patients proposed by the Asian Pacific type 2 diabetes pol-
icy group [14]. For BMI, we referred to the WHO cut-off
points for Asian populations: 23 to 27.5 kg/m2 (defined in
the study as overweight) and 27.5 kg/m2  or above
(defined in the study as obese) [15].
We examined the evolution of these same parameters over
time by calculating the mean and standard deviation at
regular intervals after treatment initiation. We used the t
test to compare the mean differences between paired val-
ues at baseline and at month 6 for glucose, BP, and BMI.
We assessed the following potential risk factors for loss to
follow-up: age, sex, type of diabetes, year of admission,
geographical origin, BMI, baseline BP and last consulta-
tion (late or not late). A logistic regression model was per-
formed to assess the association of these potential risk
factors with the outcome of lost to follow-up.
We analyzed patient data using Microsoft Excel (Red-
mond, WA, USA) and STATA software, version 8.2
(STATA, College Station, TX, USA). The analysis consid-
ered data from the beginning of the program in 2002 until
June 2008. No consent was obtained from individual
patients. The use of the medical record data for research
purposes was approved by the Ethical Review Board of
MSF.BMC Medicine 2009, 7:33 http://www.biomedcentral.com/1741-7015/7/33
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Results
Characteristics of study participants and cohort outcomes
A total of 4,404 diabetic patients were registered in the 2
clinics over the 5-year period. Patient characteristics are
presented in Table 1. Patients were nearly all diagnosed
with type 2 diabetes (99%), were predominantly women,
and 64% were ≥50 years old. Over a fifth of patients orig-
inated from outside the provinces where the two clinics
were located. The median follow-up period per patient
was 20 months (interquartile range (IQR) 5 to 39
months). Patients not lost to follow-up underwent an
average of 10 consultations per year. At the time of diag-
nosis, 56% patients were overweight and 16% were obese.
Only 4% of patients were prescribed insulin at their last
consultation and 41% (1,601/3,952) of patients on oral
treatment were prescribed 2 antidiabetic drugs at their last
consultation. By the end of the observation period, 2,737
(62%) patients were active on treatment, 24 (0.5%) had
died, 135 (3%) were transferred to another clinic, and
1,508 (34%) were LTFU (missed a scheduled appoint-
ment by over 3 months) (Figure 1). Most LTFU events
(74%) occurred within the first year after diagnosis.
Glucose, BP, and weight control
The proportions of patients (with baseline and follow-up
values and not LTFU) reaching the recommended targets
for glucose and BP are shown in Figure 2. In all, 24% (51/
210) of patients had a HbA1c concentration below 7%
and 35% (709/1,995) had an RBG less than 145 mg/dl
within 1 year. In all, 45% (327/723) and 62% (373/605)
of patients with systolic or diastolic hypertension at base-
line, respectively, reached the treatment goals of ≥130/80
mm Hg within 1 year. As for weight control, only 22%
(90/401) patients with obesity at baseline lowered their
BMI below 27.5 kg/m2 after 1 year.
Figure 3 illustrates the evolution of the mean values for
RBG, HbA1c, BP and BMI over treatment time. Except for
BMI, other parameters showed an initial drop during the
first 6 months of treatment, which was maintained over
the 5-year period. There was a significant drop of 109 mg/
dl (95% confidence interval (CI) 103.1 to 114.3) in the
mean RBG (P < 0.001) and a drop of 2.7% (95% CI 2.3 to
3.0) in the mean HbA1c (P < 0.001) between baseline and
month 6 (Table 2). Among patients with hypertension at
baseline, there was a drop of 13.5 mm Hg (95% CI 12.1
to 14.9) in the mean SBP (P < 0.001), and a drop of 11.7
mm Hg (95% CI 10.8 to 12.6) in the mean DBP (P <
0.001) between baseline and month 6.
Risk factors for loss to follow-up
We included a total of 3,953 diabetic patients registered
from 2002 until February 2008 who had attended at least
2 consultations in the analysis of risk factors for LTFU. We
included all factors with a P value < 0.05 in the univariate
analysis in the logistic regression model (Table 3). Factors
significantly associated with LTFU were male gender, age
older than 60 years, living outside the province, normal
BMI (<23 kg/m2) on admission, high RBG (≥180 mg/dl)
on last consultation, and coming late for the last consul-
tation.
Discussion
The treatment outcomes of this large cohort of patients
receiving standardized care in a resource-limited, chronic
disease clinic setting with high prevalence of diabetes are
encouraging. They support the feasibility of providing rea-
sonably good care for large numbers of patients in devel-
oping countries. Overall, significant improvements in
glycemia and BP were observed in patients within the first
6 months of treatment and were maintained throughout
the study period. Nearly all patients had type 2 diabetes
and were treated mainly with oral antidiabetic drugs.
Unfortunately, although most patients improved, the
majority did not reach the recommended targets for opti-
mal diabetes control. Despite this, in light of the evidence
that a decrease in glycosylated hemoglobin level is associ-
ated with a decreased risk for cardiovascular disease and
mortality in persons with type 2 diabetes [5,6], patients
with improved glycemia likely gained some clinical bene-
fit even if they did not reach the target.
Other studies in both high and low resource countries
have shown that the treatment targets for blood glucose in
Outcome of diabetic patients diagnosed in 2002 to 2008 at  end of study period (June 2008) Figure 1
Outcome of diabetic patients diagnosed in 2002 to 
2008 at end of study period (June 2008).BMC Medicine 2009, 7:33 http://www.biomedcentral.com/1741-7015/7/33
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type 2 diabetic patients are difficult to reach in clinical
practice. Large patient studies in industrialized countries
have found relatively low proportions (24% to 36%) of
diabetic patients with HbA1c below 7% [8,11,16]. Relia-
ble data on glycemic control among diabetic patients
treated in middle-income and low-income countries is
more limited but no better. For instance, the goal for
HbA1c below 7% was only reached by between 20% and
30% of patients treated in Thailand, in primary health
care settings and at the tertiary hospital level, respectively
[17,18], and by 46% of a cohort in Brazil [19]. In three
Caribbean countries, 50% of patients had "poor" blood
glucose control (≥10 mmol/l RBG) [20]. Results from
small samples of patients in other low resource settings
were similar: a median HbA1c of 8.5% was obtained in
patients enrolled in a diabetic program in Eritrea [21], and
64% of patients showed poor control of HbA1c (>10%)
over a 1-year period in Papua New Guinea [22]. In the
Seychelles, less than a quarter of diabetic persons under
treatment achieved recommended treatment target [23].
Although comparable to results from high-income coun-
tries, the quality of diabetes care in middle-income and
low-income countries, from the limited findings pub-
lished so far, is not optimal.
The reasons for disappointing optimal glucose control
results in this setting are multifactorial and include poor
adherence to taking medication, the use of RBG instead of
HbA1c for patient monitoring, poor weight control, and
lack of therapy intensification, such as insulin (<4% of
patients on insulin). The very low number of patients on
insulin in our study reflects the programmatic challenges
of delivering insulin in a resource-constrained setting. In
comparison, in the USA, around 30% of adults with dia-
betes are using insulin, either alone or combined with oral
medication [24]. Barriers to the use of insulin in our set-
Table 1: Characteristics of diabetic patients registered in clinics (March 2002–June 2008)
Characteristic Value
Total no. of diabetic patients registered 4,404
Type of diabetes, n (%):
Type 1 54 (1.2%)
Type 2 4,350 (98.8%)
Age in years, median (IQR) 53 (46 to 60)
Age group in years, n (%):
≥39 438 (10.0%)
40 to 49 1,168 (26.5%)
50 to 59 1,540 (35.0%)
≥60 1,258 (28.6%)
Women, n(%) 2,905 (66.0%)
Origin of patients*, n (%):
District of clinic 1,724 (41.2%)
Other districts of province 1,550 (37.0%)
Outside province 912 (21.8%)
Random plasma glucose on admission, median (IQR) 272 (196 to 376)
Random plasma glucose <180 mg/dl, n (%) 797/4,095 (19.5%)
HbA1c on admission %, median (IQR) (n = 950) 11.5 (9.1 to 13.5)
HbA1c <7%, n (%) 59/950 (6.2%)
Blood pressure on admission, n (%):
Systolic ≥140 mm Hg 1,555/3,840 (40.5%)
Diastolic ≥90 mm Hg 1,316/3,840 (34.3%)
BMI on admission, kg/m2, median (IQR) (n = 4337):
All patients 23.5 (20.9 to 26)
Men 23 (20.1 to 26)
Women 23.7 (21.1 to 26.2)
BMI ≥23 kg/m2, n (%) 2,433/4,337 (56.1%)
BMI ≥27.5 kg/m2, n (%) 686/4,337 (15.8%)
Treatment on last consultation, n (%):
No antidiabetic drug 91 (2.2%)
Oral antidiabetic drug(s) alone 3,911 (94.1%)
Insulin alone 115 (2.8%)
Oral antidiabetic drug(s) plus insulin 41 (1.0%)
No data 246
*Data on origin available only for patients admitted until February 2008.
BMI = body mass index; HbA1c = glycosylated hemoglobin; IQR = interquartile range.BMC Medicine 2009, 7:33 http://www.biomedcentral.com/1741-7015/7/33
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ting include the financial cost, problems with cold chain
storage, cost of and difficulties learning how to use glu-
cose monitoring equipment, and less than ideal education
and support for patient self-management. In a study in
Brazil where 55% of type 2 diabetic patients were on insu-
lin, problems in adjusting the insulin dose at home possi-
bly led to poorer results among insulin-treated patients as
compared to those using oral hypoglycemic agents [19].
Thus, although insulin is needed for therapy intensifica-
tion, its proper use by patients remains challenging in
resource-constrained settings.
With regard to hypertension, in industrialized countries it
is estimated that only 30% of patients treated achieve
their target BP goals, mainly due to poor adherence to
treatment [25]. BP control was achieved in less than a
quarter of diabetic persons under treatment in a poor Afri-
can setting [23]. In light of these figures, the high propor-
tion of patients with hypertension on admission who
reached the BP targets was satisfactory in our program.
However, we acknowledge that regression to the mean
and habituation to repeated BP measurements could have
had an effect on the decrease in BP observed during fol-
low-up [26].
Weight control results in our diabetic cohort were poor
and could be, in part, due to insufficient and inadequate
patient education. Lifestyle changes imply both environ-
mental and behavioral changes. In our context we cannot
exclude a cultural reluctance to lose weight, since there is
no dietary advice and no promotion of physical exercise at
the population level in the country. This is compounded
by the fact that in Cambodia, the rice-dominated diet is
carbohydrate rich and most of the population living in
urban and semi-urban areas tend to adopt a sedentary life-
style. We suggest that the lack of adequate dietary advice
and weight control could also have contributed to the per-
sisting hyperglycemia observed.
The high LTFU observed among this cohort of diabetic
patients contrasts with the low LTFU documented among
HIV/AIDS patients treated in the same chronic disease
clinic (3%) [12]. One contributing factor could be the ine-
quality in care: HIV/AIDS patients received free health
Proportion of diabetic patients reaching the recommended optimal targets Figure 2
Proportion of diabetic patients reaching the recommended optimal targets. For body mass index (BMI), only 
patients with elevated baseline BMI (≥23.0) were included in the analysis. For systolic blood pressure (SBP), only patients with 
elevated baseline SBP (>130 mm Hg) were included in the analysis. For diastolic blood pressure (DBP), only patients with ele-
vated baseline DBP (>80 mm Hg) were included in the analysis.
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Evolution of mean with standard deviation of biological markers in diabetic patients under treatment Figure 3
Evolution of mean with standard deviation of biological markers in diabetic patients under treatment. Evolution 
of (a) random blood glucose (RBG), (b) hemoglobin A1c (HbA1c), (c, d) blood pressure (BP) and (e) body mass index (BMI) 
in diabetic patients with baseline and follow-up values and not lost to follow-up. For BMI, only patients with elevated baseline 
BMI (≥23.0) were included in the analysis. For systolic BP (SBP), only patients with elevated baseline SBP (>130 mm Hg) were 
included in the analysis. For disastolic BP (DBP), only patients with elevated baseline DBP (>80 mm Hg) were included in the 
analysis.
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care, money for transportation, food, and social support,
while diabetic patients did not get any of those benefits
[27]. In our cohort, patients 60 years or older, patients late
for their last appointment, and those living outside the
province were more likely to be lost to follow-up. Older
patients are unlikely to work and depend on family mem-
bers for living and health expenditures, such as transport
and drugs, over which they have no control. Another fac-
tor is that diabetic patients, contrary to HIV patients, have
several alternatives for care such as traditional medicine
and local pharmacies. Finally, the weakness of the coun-
seling and patient education components of the diabetic
care probably led to an insufficient understanding by
patients of the disease and its consequences if untreated,
leading to reduced motivation to continue treatment.
Although the integration of diabetic care within an HIV
service allowed for a rationalization of resources [12],
there were program costs related specifically to diabetic
care that were not covered by the HIV program. For
instance, in Cambodia HbA1c is only available in two
locations and is at least eight times more expensive than
Table 2: Mean differences between paired observations at baseline and month 6 in patients with baseline and follow-up values and not 
lost to follow-up
Mean difference between baseline and month 6 (95% CI)* P value for t test
RBG, mg/dl (n = 2,725) 108.7 (103.1 to 114.3) < 0.001
HbA1c, % (n = 824) 2.7 (2.3 to 3.0) < 0.001
SBP, mm Hg (n = 801) 13.5 (12.1 to 14.9) < 0.001
DBP, mm Hg (n = 688) 11.7 (10.8 to 12.6) < 0.001
BMI, kg/m2 (n = 1,364) -0.4 (-0.5 to -0.3) < 0.001
For BMI, only patients with elevated baseline BMI (≥23.0) were included in the analysis. For SBP, only patients with elevated baseline SBP (>130 mm 
Hg) were included in the analysis. For DBP, only patients with elevated baseline DBP (>80 mm Hg) were included in the analysis.
*Mean difference between two observations taken on each individual.
BMI = body mass index; DBP = diastolic blood pressure; RBG = random blood glucose; SBP = systolic blood pressure.
Table 3: Predictors of loss to follow-up (LTFU) among diabetic patients* (n = 3,953) by logistic regression analysis
Factors LTFU cases/patients, (%) OR 95% CI P value aOR† 95% CI P value
Sex (n = 3,953):
Male 430/1,332 (32.3) 1.0 1.0
Female 731/2,621 (27.9) 0.81 0.70 to 0.94 0.004 0.79 0.67 to 0.93 0.005
Age, years (n = 3952):
≥39 118/384 (30.7) 1.0 1.0
40 to 49 242/1,056 (22.9) 0.67 0.52 to 0.87 0.003 0.72 0.54 to 0.98 0.034
50 to 59 389/1,395 (27.9) 0.87 0.68 to 1.11 0.27 1.02 0.77 to 1.36 0.878
≥60 412/1,117 (36.9) 1.32 1.02 to 1.69 0.03 1.54 1.15 to 2.05 0.004
Type of diabetes
(n = 3953):
Type 1 20/42 (47.6) 1.0 1.0
Type 2 1,141/3,911 (29.2) 0.45 0.25 to 0.83 0.01 0.50 0.25 to 1.01 0.053
Origin (n = 3952):
District of clinic 460/1,641 (28.0) 1.0 1.0
Other districts 391/1,473 (26.5) 0.93 0.79 to 1.09 0.35 1.01 0.84 to 1.21 0.88
Outside province 310/838 (37.0) 1.51 1.26 to 1.80 <0.001 1.68 1.38 to 2.06 <0.001
Last BMI, kg/m2, (n = 3901):
<23.0 581/1,708 (34.0) 1.0 1.0
≥23.0 547/2,193 (24.9) 0.64 0.56 to 0.74 <0.001 0.70 0.60 to 0.82 <0.001
Last RBG, mg/dl (n = 3659):
<180 330/1,688 (19.6) 1.0 1.0
≥180 621/1,971 (31.5) 1.89 1.62 to 2.21 <0.001 1.81 1.54 to 2.13 <0.001
Last consultation (n = 3927):
Not late 686/2,960 (23.2) 1.0 1.0
Late 474/967 (49.0) 3.19 2.74 to 3.71 <0.001 2.72 2.29 to 3.24 <0.001
*Included are all patients who initiated treatment between March 2002 and February 2008 and who attended at least two consultations.
†All factors with P value < 0.05 in univariate analysis were included in the multivariable regression model. P value for the likelihood ratio test for the 
model was <0.001.
aOR = adjusted odds ratio; BMI = body mass index; CI = confidence interval; OR = odds ratio; RBG = random blood glucose.BMC Medicine 2009, 7:33 http://www.biomedcentral.com/1741-7015/7/33
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CD4 count, used for monitoring HIV patients on antiret-
roviral therapy (ART). Additionally, other effective meas-
ures to reduce cardiovascular risks such as lipid-lowering
drugs (statins) were beyond the program's financial
capacity. However, the estimated cost for drug therapy
based on the local drug prices was rather affordable at
approximately US$48 per year for monotherapy (gliben-
clamide) and US$192 per year for bitherapy (glibencla-
mide and metformin). But overall, without free care
offered by MSF, laboratory and drug costs, if assumed by
patients, could act as barriers to meeting treatment goals.
This study has certain limitations. First, even though data
were collected in standardized patient forms and entered
prospectively into specifically designed software, errors or
omissions could have occurred as data was collected from
an operational program that was not designed specifically
for research purposes. Second, we acknowledge that we
only used biological measurements, such as glycemia and
BP, as surrogate markers for diabetic outcomes. Addition-
ally, the lack of standardized case definitions, access to
specialized diagnosis and care for complications pre-
vented us from collecting information about complica-
tions. Third, deaths were likely underestimated in our
cohort and misclassified as LTFU, as we had no way of
checking up on defaulters. The prognosis for diabetes in
low-resource settings is poor for many patients as shown
by the 5-year survival rates (60% to 84%) observed in dia-
betic patients in Africa [28]. Mortality surveillance and a
defaulter tracing system were not in place in our program,
as they required resources beyond our capacity. Fourth,
our results only reflect treatment outcomes in diabetic
patients attending care on a regular basis. By excluding
patients LTFU in the analysis of treatment outcome, we
introduced bias in the findings towards better results than
there were in reality. Finally, until the last year of the pro-
gram, we could only use RBG to estimate glycemic control
instead of the gold standard, HbA1c, an expensive test and
one not widely available test in our setting. Although a
few studies have concluded that using RBG can be used to
predict the quality of diabetic control in resource limited
settings [13,29], we believe HbA1c provides a better meas-
ure and would encourage its use. Despite these limita-
tions, our study's strengths were its large size, relatively
lengthy follow-up, prospective data collection, and use of
a specialized data software program.
Conclusion
In conclusion, this study has shown that improvement in
key biological markers can be obtained in large numbers
of individuals with type 2 diabetes treated in a low-
resource setting. Key features were a chronic disease struc-
ture to the program, standardized diagnosis and treatment
protocols, multidisciplinary team, and heavily subsidized
care. However, we learned that other interventions to fur-
ther improve glycemic control should be pursued, includ-
ing increasing the access to and use of insulin and HbA1c
testing, and interventions to improve patient self-empow-
erment especially with regard to weight reduction. Com-
plementary actions at the population level to promote
lifestyle changes and achieve healthy body weight are also
necessary components of good diabetic care and need to
be established. These and other interventions in resource-
poor settings require further operational research to
improve care. However, our results do offer encourage-
ment for the scaling up of care for chronic diseases such as
diabetes, as they are a large and growing burden of illness
in developing countries.
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